19532-69-5

Usage

Uses

Used in Pharmaceutical Industry:
2,2-Dithiobis(5-methoxybenzoic acid) is used as an intermediate in the synthesis of various organic compounds for pharmaceutical applications. Its antioxidant and radical scavenging properties contribute to the development of new drugs and the protection of materials from degradation caused by free radicals and oxidation.
Used in Electronics Industry:
2,2-Dithiobis(5-methoxybenzoic acid) is used as a reagent in organic chemistry reactions, particularly in the electronics industry. Its properties make it useful in the creation of new functional materials, enhancing the performance and stability of electronic devices.
Used in Material Science:
2,2-Dithiobis(5-methoxybenzoic acid) is used as a component in the development of new functional materials. Its antioxidant and radical scavenging properties play a crucial role in creating materials with improved resistance to degradation and enhanced performance in various applications.

Upstream product

• 6705-03-9 2-Amino-5-methoxybenzoic acid 

Downstream Products

• 16807-37-7 5-methoxy-2-sulfanyl-benzoic acid 
• 80568-30-5 4-chloro-7-methoxy-1-methylthioxanthenone 
• 80568-28-1 1-(2-Dimethylamino-ethylamino)-7-methoxy-4-methyl-thioxanthen-9-one 
• 86456-00-0 3-chloro-7-methoxy-9H-thioxanthen-9-one 
• 86456-31-7 1-<<2-(dimethylamino)ethyl>amino>-7-hydroxy-9H-thioxanthen-9-one 
• 86456-05-5 1-<<2-(dimethylamino)ethyl>amino>-7-methoxy-9H-thioxanthen-9-one 
• 86455-91-6 1-(2-Dimethylaminoethylamino)-7-hydroxy-4-(hydroxymethyl)-9H-thioxanthen-9-one 
• 86455-90-5 1-[[2-(Diethylamino)ethyl]amino]-7-hydroxy-4-(hydroxymethyl)-9H-thioxanthen-9-one 
• 101339-44-0 1-<<2-(dimethylamino)ethyl>amino>-4-(hydroxymethyl)-7-(toluenesulfonyloxy)-9H-thioxanthen-9-one 
• 86456-33-9 1-<<2-(diethylamino)ethyl>amino>-4-(hydroxymethyl)-7-(toluenesulfonyloxy)-9H-thioxanthen-9-one 
• 86456-29-3 1-<<2-(diethylamino)ethyl>amino>-7-(toluenesulfonyloxy)-9H-thioxanthen-9-one 
• 100538-48-5 5,5'-dihydroxy-2,2'-disulfanediyl-di-benzoic acid 
• 384339-80-4 C₇H₆O₃S 
• 793725-10-7 5-methoxydithiosalicylic acid di-2-chloroethyl amide 

Relevant academic research and scientific papers

COMPOUNDS AND METHODS FOR MODULATING ACTIVITY OF CALCIUM RELEASE CHANNELS

The present teachings provide compounds of Formulae I and II: and and pharmaceutically acceptable salts, hydrates, complexes, esters, and prodrugs thereof, wherein R1, R1', R2, R2', R3, R3', and X are as defined herein. The present teachings also provide methods of making the compounds of formulae I and II, and methods of treating RyR-associated conditions, disorders, and diseases that include administering a therapeutically effective amount of a compound of formula I or II to a subject in need thereof. In addition, the present teachings relate to methods of reducing the open probability of a ryanodine receptor, and methods of reducing Ca2+ release across a ryanodine receptor (e.g., into the cytoplasm of a cell), by contacting a compound of formula I or II with a ryanodine receptor.

Novel agents for preventing and treating disorders involving modulation of the RyR receptors

The present invention provides novel compounds of Formula I and salts, hydrates, solvates, complexes, and prodrugs thereof. The present invention further provides methods for synthesizing compounds of Formula I. The invention additionally provides pharmaceutical compositions comprising the compounds of Formula I and methods of using the pharmaceutical compositions of Formula I to treat and prevent disorders and diseases associated with the RyR receptors that regulate calcium channel functioning in cells. Such disorders and diseases include, by way of example only, cardiac disorders and diseases, skeletal muscular disorders and diseases, cognitive disorders and diseases, malignant hyperthermia, diabetes, and sudden infant death syndrome. Cardiac disorder and diseases include, but are not limited to, irregular heartbeat disorders and diseases; exercise-induced irregular heartbeat disorders and diseases; sudden cardiac death; exercise-induced sudden cardiac death; congestive heart failure; chronic obstructive pulmonary disease; and high blood pressure. Irregular heartbeat disorders and diseases include and exercise-induced irregular heartbeat disorders and diseases include, but are not limited to, atrial and ventricular arrhythmia; atrial and ventricular fibrillation; atrial and ventricular tachyarrhythmia; atrial and ventricular tachycardia; catecholaminergic polymorphic ventricular tachycardia (CPVT); and exercise-induced variants thereof. Skeletal muscular disorder and diseases include, but are not limited to, skeletal muscle fatigue, exercise-induced skeletal muscle fatigue, muscular dystrophy, bladder disorders, and incontinence. Cognitive disorders and diseases include, but are not limited to, Alzheimer's Disease, forms of memory loss, and age-dependent memory loss.

Novel anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof

The present invention provides methods for limiting or preventing a decrease in the level of RyR2-bound FKBP12.6 in a subject. The present invention further provides methods for treating and preventing atrial and ventricular cardiac arrhythmias, heart failure, and exercise-induced sudden cardiac death in a subject. Additionally, the present invention provides use of JTV-519 in a method for limiting or preventing a decrease in the level of RyR2-bound FKBP12.6 in a subject who has, or is a candidate for, atrial fibrillation. Also provided are uses of 1,4-benzothiazepine derivatives in methods for treating and preventing atrial and ventricular cardiac arrhythmias and heart failure in a subject, and for preventing exercise-induced sudden cardiac death. The present invention also provides methods for identifying agents for use in treating and preventing atrial fibrillation and heart failure, and agents identified by these methods.